Roche Pharmaceutical Development and Sales Overview

2022 outlook Group sales growth¹ Core EPS growth¹ • Stable to low-single digit • Dividend outlook • 1 At Constant Exchange Rates (CER) Low- to mid-single digit Further increase dividend in Swiss francs Roche 49 49

View entire presentation